WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
about
Is lipid signaling through cannabinoid 2 receptors part of a protective system?Therapeutic potential of monoacylglycerol lipase inhibitorsExpression Analysis of CB2-GFP BAC Transgenic MiceCB2 receptor activation prevents glial-derived neurotoxic mediator production, BBB leakage and peripheral immune cell infiltration and rescues dopamine neurons in the MPTP model of Parkinson's disease.Edaravone guards dopamine neurons in a rotenone model for Parkinson's diseaseTargeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative DisordersExcess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agentsRecent advances in methamphetamine neurotoxicity mechanisms and its molecular pathophysiologyCannabinoid Type 2 (CB2) Receptors Activation Protects against Oxidative Stress and Neuroinflammation Associated Dopaminergic Neurodegeneration in Rotenone Model of Parkinson's DiseaseIn vivo pharmacology of endocannabinoids and their metabolic inhibitors: therapeutic implications in Parkinson's disease and abuse liabilityThe K2/Spice phenomenon: emergence, identification, legislation and metabolic characterization of synthetic cannabinoids in herbal incense products.CB2: a cannabinoid receptor with an identity crisisA synthetic cannabinoid agonist promotes oligodendrogliogenesis during viral encephalitis in ratsEndocannabinoids prevent β-amyloid-mediated lysosomal destabilization in cultured neurons.Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury.Cannabinoid Receptor 2 Signaling in Neurodegenerative Disorders: From Pathogenesis to a Promising Therapeutic Target.CB2 receptor agonists protect human dopaminergic neurons against damage from HIV-1 gp120.Immunoregulation of a CB2 receptor agonist in a murine model of neuroAIDSThe therapeutic potential of cannabinoids for movement disorders.Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's diseasePromising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotectionEndocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation.Cannabinoid modulation of neuroinflammatory disorders.New insights on endocannabinoid transmission in psychomotor disorders.The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiationCannabinoids and Dementia: A Review of Clinical and Preclinical Data.Comparison of the D2 receptor regulation and neurotoxicant susceptibility of nigrostriatal dopamine neurons in wild-type and CB1/CB2 receptor knockout miceLoss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.Modulating the endocannabinoid system in human health and disease--successes and failuresPrior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors.Central CB2 receptors in inflammation-driven neurodegeneration: dysregulation and therapeutic potentialTracMouse: A computer aided movement analysis script for the mouse inverted horizontal grid testMarijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.Changes in CB(1) and CB(2) receptors in the post-mortem cerebellum of humans affected by spinocerebellar ataxias.Prospects for cannabinoid therapies in basal ganglia disorders.Immunomodulatory properties of kappa opioids and synthetic cannabinoids in HIV-1 neuropathogenesis.Endocannabinoid modulation of dopaminergic motor circuits.The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects.Cannabinoid Signaling and Neuroinflammatory Diseases: A Melting pot for the Regulation of Brain Immune Responses.Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications.
P2860
Q24633122-ED361241-96E5-47F3-9C13-ABF62015B9D1Q26991513-DF99F2A2-5B15-4745-AA6A-351D67DCB884Q27316448-B555CF28-9FD2-43E9-AF63-59B6A5F92C84Q27324500-0A42ED3F-F745-49BA-B6AC-1F5D1E0AF2B4Q27335848-51B6B438-5784-4C13-9AE2-BAC83C473848Q28073952-CD1C0A59-E0D0-4D92-A03D-CE95D0FD44F6Q28075692-DA9816A8-D00D-4A8B-81BF-4C2DC977F0E4Q28260273-95431E08-A102-4E19-AAF7-FFBDE18F5C2EQ28277871-E016451C-3AF6-4909-9F4F-0213512863C6Q33751118-169C7B23-B949-40A2-A437-88A5BD8DA4FAQ33908169-C4E5F5A5-B49A-4EEB-A1D2-F95AD023ADEFQ34098185-2BFA582C-AC04-43AC-B540-9F8E6E41CE06Q34308648-3F89EEE8-ACFF-4795-B0CE-5F2D0083EFF1Q34352311-9317E795-E794-4DBD-93F9-BE2CF3420B10Q34591087-F6C65059-ED26-46E2-BA1F-5759984256D7Q34680801-E5F84757-86C9-4E44-ACC0-EF8C6C35E18DQ35023230-B9FEB23F-3834-4C64-8D78-90D5128E6134Q35028750-CEB497B7-C143-4294-8FAE-0728B577E030Q35171113-9EDB6583-654B-4B73-BA29-567EBE85CA69Q35193305-C29554BB-3E29-4643-8642-E2B8E59163B2Q35499568-E9F16AA4-EBD2-4B1A-8298-0B0362B48C16Q35645037-BFB0EFCF-B0A0-4EB7-B622-3CF564388A31Q36067324-676737E3-0A00-40A5-A2AC-4A35D3D0E059Q36074595-AE27113C-09C5-4DB0-886C-0961502752A7Q36130163-023B475D-D274-46B5-8E7D-149DBAC59871Q36155898-C01C37F3-6630-429D-864B-4EA6C4B40437Q36343135-8D3B821A-4051-419E-B93A-E932E6E74FB3Q36861976-8709DA5D-869E-4888-AFED-A313FBFB9294Q36933683-3BF63984-1769-481D-AC62-62FECAB475A6Q37082410-9AC01A74-49B7-49A6-B933-B0B719D5C0B2Q37387247-5999778C-BEC0-4C9B-AB73-F96198B834C4Q37508349-2849D3FF-3E0D-4BA9-B5C8-9F43855880B1Q37512670-A4E2A8AA-38DD-440E-98B6-A6AAACC69F9EQ37637769-9EC30177-B182-4C0E-8E8A-0F9729AEE30FQ37872326-01B2D158-1C5D-41E9-BE4A-062F5C865A03Q37919370-2DCB4846-76DF-4219-8E5B-530BF1E41FE1Q38018946-CD654AB3-9B67-45F8-A8D5-3261B2FF7AFEQ38072364-903AF410-F3F3-49FF-84B1-A7E4A12C4C24Q38324480-64D781CF-95EF-4137-9650-C839348546B4Q38563981-1D6EF450-846B-4877-B705-5B0AF7929872
P2860
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 May 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
WIN55,212-2, a cannabinoid rec ...... model of Parkinson's disease.
@en
WIN55,212-2, a cannabinoid rec ...... model of Parkinson's disease.
@nl
type
label
WIN55,212-2, a cannabinoid rec ...... model of Parkinson's disease.
@en
WIN55,212-2, a cannabinoid rec ...... model of Parkinson's disease.
@nl
altLabel
WIN55,212-2, a cannabinoid rec ...... e model of Parkinson’s disease
@en
prefLabel
WIN55,212-2, a cannabinoid rec ...... model of Parkinson's disease.
@en
WIN55,212-2, a cannabinoid rec ...... model of Parkinson's disease.
@nl
P2093
P2860
P921
P1476
WIN55,212-2, a cannabinoid rec ...... e model of Parkinson's disease
@en
P2093
Alex A Martinez
Alexandre Seillier
Andrea Giuffrida
David A Price
James L Roberts
Randy Strong
Wouter Koek
Yolanda Acosta
P2860
P304
P356
10.1111/J.1460-9568.2009.06764.X
P407
P577
2009-05-21T00:00:00Z